Jate Samathivathanachai
Chief Business and Financial Officer at Foundery Innovations
San Francisco Bay Area
Overview
Work Experience
Senior Vice President, Finance
2025 - Current
Mammoth Biosciences is a biotechnology company focused on leveraging its proprietary ultracompact CRISPR systems to develop potential long-term curative therapies for patients with life-threatening and debilitating diseases. Founded by CRISPR pioneer and Nobel laureate Jennifer Doudna and Trevor Martin, Janice Chen, and Lucas Harrington, the company’s ultracompact systems are designed to be more specific and enable in vivo gene editing in difficult to reach tissues utilizing both nuclease applications and new editing modalities beyond double stranded breaks, including base editing, reverse transcriptase editing, and epigenetic editing.
Mammoth Biosciences develops novel CRISPR applications for disease detection, research, agriculture, biodefense, and more.
Raised $264,545,000.00 from Bradley Horowitz, Plum Alley, Decheng Capital, Senator Investment Group, Redmile Group, Sixth Street, Foresite Capital, NFX, Tachyon Ventures and Mayfield Fund.
Consultant | Advisor, Finance and Business Development
2024
Abyssinia develops next-generation immunotherapies, blood & CSF based diagnostics, and vaccine candidates for neurodegenerative diseases through the precision targeting of toxic misfolded protein aggregates. The Company's first antibody is focused on Alzheimer's Disease and uniquely targets oAβ.
Investor
2020
Life Science Angels (LSA) is a not-for-profit corporation with 130-150 accredited investor members and 12-18 highly qualified fellows. LSA has invested >$60M in over 100 startups in the biopharma, medical device, diagnostics and digital health sectors. Companies seeking funding are encouraged to apply via www.lifescienceangels.com/apply-for-funding. Investments: - Avisi Technologies - Celldom - InnoSIGN - Noctrix Health - Pelvital - Renata Medical - Saccharo - TRIO Pharmaceuticals - VisiCELL Medical
Investor
2020
Hyphen Capital is a syndicate of accredited angel investors which invests in multi-stage companies started by Asian American and Pacific Islander founders. Investments: - Arc - Baobab Studios - BrewBird - Canopy - Concha Labs - Dang Foods - Elation Health - Hero Bread - Homecourt - Italic - Mascot - Mayvenn - Prime Roots - Pry Financials - Rocket Dollar - SafeBase - Slope - Snapcommerce - Unit21 - Yumi
Investor
2020
The Berkeley Angel Network (BAN) is a group of angel investors who are alumni, faculty and former faculty of UC Berkeley. Companies seeking funding may refer to the following process document: https://berkeleyangelnetwork.com/wp-content/uploads/2017/08/BAN-Berkeley-Angel-Network-Application-Process-20150409-GAW.pdf Investments: - Nalu Bio - Noninvasix - Sensorygen
Berkeley Angel Network is a venture capital and private equity firm that specializes in the fields of finance and investment management.
Angel Investor
2012
Selected Investments: - Blueberry Pediatrics - LB Pharmaceuticals - Neuraptive Therapeutics - Root Applied Science - Sushiritto | Mochiko Mochi Pizza - TauRx Therapeutics - Vanity | Suite26
Chief Business and Financial Officer
2022 - 2025
Foundery is a venture studio fund focused on investing in first-in-class immunotherapies sourced from premier research universities. Foundery validates and develops early drug concepts to generate advanced development candidate (DC) packages in collaboration with university investigators. NewCos are built around DCs and sold to biopharma partners for downstream clinical development.
Vice President, Head of Finance and Corporate Development
2022 - 2022
Tranquis is an SR One/Remiges/Vivo backed clinical-stage biopharmaceutical company developing a portfolio of small molecule therapeutics based on its unique approach of reprogramming dysfunctional myeloid immune cells to restore normal cell homeostasis and function.
Senior Director, Business Development, Licensing and M&A
2019 - 2022
Horizon was a global biotechnology company focused on the discovery, development and commercialization of medicines that address critical needs for people impacted by rare, autoimmune and severe inflammatory diseases. Amgen completed its $27.8B acquisition of Horizon in October 2023.
Horizon Therapeutics focuses on the development of prescription drugs for mild to moderate pain relief and arthritis.
Raised $4,458,516,447.00 from Cowen Group, Deerfield, Citigroup Global Markets, Silicon Valley Bank, Oxford Finance LLC and Kreos Capital.
Country Head
2015 - 2019
Allexcel was the exclusive marketer and master distributor of Red Bull Energy Drink (Asian SKUs) in Malaysia.